Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. develops monoclonal antibody therapies for serious viral infectious diseases, with an initial focus on SARS-CoV-2. Company news commonly covers PEMGARDA (pemivibart), which received U.S. FDA emergency use authorization for pre-exposure prevention of COVID-19 in certain immunocompromised individuals, and pipeline work involving VYD2311 for COVID-19, VBY329 for RSV, and VMS063 for measles.
Updates also address clinical-study design and tolerability research, antibody platform presentations, financial results and corporate updates, public education efforts around antibodies and immune health, and Nasdaq inducement equity grants under the company’s 2026 Inducement Plan.
Invivyd (IVVD) will participate in three investor conferences in New York in September 2026, featuring Chairman and CEO Marc W. Elia and other management members.
The company will attend Citi’s 2026 Biopharma Back to School Conference on September 9 (meetings only), the Cantor Global Healthcare Conference with a fireside chat on September 10 at 9:45 AM ET, and the H.C. Wainwright 28th Annual Global Investment Conference with a fireside chat on September 14 at 5:00 PM ET. Live webcasts of the fireside chats will be accessible and archived in the investor section of Invivyd’s website.
Invivyd (IVVD) granted stock options as inducement awards to six newly hired non-executive employees on September 1, 2026.
The employees received options to purchase an aggregate of 255,000 shares of Invivyd common stock under the 2026 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a per share exercise price of $0.8799, equal to the closing price on the grant date, and a 10-year term. Each option vests over four years, with 25% vesting on the first anniversary of the employee’s start date and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
Invivyd (Nasdaq: IVVD) appointed Chairman Marc Elia as Chief Executive Officer, combining the roles of Chairman and CEO. Ajay Royan, founder of Mithril Capital and a long-term investor in Invivyd, was named Lead Independent Director. The company also added healthcare investor Ian Sheffield, founder and Managing Partner of North Country Holdings, to its Board as an independent director.
Invivyd reiterated that top-line data from its VYD2311 COVID-19 monoclonal antibody program are expected around the end of Q3 2026. Depending on these results, the company plans either a traditional or Accelerated Approval Biologics License Application pathway for VYD2311, subject to FDA review and approval.
Invivyd (Nasdaq: IVVD) reported Q2 2026 PEMGARDA® net product revenue of $14.3 million, up 21% from $11.8 million in Q2 2025, driven by higher patient demand. Ending cash and cash equivalents were $160.1 million, which the company anticipates will fund operations through the DECLARATION pivotal data readout and support potential commercial launch readiness for VYD2311.
The pivotal DECLARATION Phase 3 trial of VYD2311 completed enrollment and is approaching its planned analysis, with top-line data planned later in Q3 2026. The LIBERTY Phase 3 trial is fully dosed, with top-line data expected in late Q3 2026. Invivyd is also advancing additional monoclonal antibody candidates, including VMS063 for measles and VBY329 for RSV, toward IND readiness in 2H 2026.
Q2 2026 R&D expenses rose to $29.4 million from $9.6 million, SG&A to $29.5 million from $16.6 million, and net loss increased to $44.4 million from $14.7 million, with net loss per share of $0.14 versus $0.12 a year earlier.
Invivyd (Nasdaq: IVVD) reported that on August 1, 2026, it granted stock options to ten newly hired non-executive employees to purchase an aggregate of 277,500 common shares under the 2026 Inducement Plan, as material inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have a per-share exercise price of $0.535, equal to the July 31, 2026 closing price of Invivyd’s stock. Each option vests over four years, with 25% vesting on the first anniversary of the employee’s start date and the remainder vesting in equal monthly installments, subject to continued service. The options have a 10-year term and remain subject to the plan’s terms.
Invivyd (Nasdaq: IVVD) received FDA notice that the Emergency Use Authorization (EUA) for PEMGARDA will terminate on June 29, 2027, following HHS’ planned end of the COVID-19 EUA declaration.
The company remains in dialogue with FDA on next regulatory steps and believes existing clinical and post-authorization data can support a future Biologics License Application for PEMGARDA, a monoclonal antibody used for COVID-19 pre-exposure prophylaxis in certain immune-compromised patients.
Invivyd (Nasdaq: IVVD) granted stock options as employment inducements under Nasdaq Listing Rule 5635(c)(4). On July 1, 2026, 14 newly hired non-executive employees received options for an aggregate 493,000 common shares at an exercise price of $0.8544 per share.
Each option vests over four years, with 25% vesting on the first anniversary of the employee’s start date and the remainder vesting in equal monthly installments, subject to continuous service. The options have a 10-year term and were issued under the 2026 Inducement Plan.
Invivyd (Nasdaq: IVVD) completed enrollment in its Phase 3 LIBERTY trial evaluating investigational COVID-19 antibody VYD2311 versus an mRNA COVID-19 vaccine in healthy adults. The randomized, double-blind study focuses on side effects and tolerability over seven days and also assesses safety and immune response when VYD2311 and vaccine are given together. Initial topline data are expected in Q3 2026 and may be reported with results from the pivotal DECLARATION trial, both within the broader REVOLUTION program supporting VYD2311 as a potential COVID-19 prevention option.
Invivyd (Nasdaq: IVVD) dosed first participants in LIBERTY, a Phase 3 trial in healthy adults evaluating the safety, tolerability, and immunology of COVID-19 prevention with VYD2311, mRNA vaccine, and their co-administration.
The trial, part of the broader REVOLUTION program with pivotal DECLARATION, plans ~210 participants and targets topline data in Q3 2026.
Invivyd (Nasdaq: IVVD) granted stock options as inducement awards to new employees. On June 1, 2026, 17 newly hired non-executive employees received options to purchase an aggregate of 513,500 shares under the 2026 Inducement Plan, compliant with Nasdaq Listing Rule 5635(c)(4).
The options have a $1.22 per share exercise price, a 10-year term, and vest over four years, with 25% vesting after one year and the remainder vesting monthly, subject to continuous service.